, Volume 225, Issue 3, pp 505–518 | Cite as

Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold?

  • Gary Remington
  • Ofer Agid
  • George Foussias
  • Larissa Ferguson
  • Krysta McDonald
  • Valerie Powell



Clozapine levels are advocated in the monitoring of patients on this drug and have now been used for a number of years. A safety-related threshold has also been proposed, as well as therapeutic lower and upper thresholds. While there has been reasonable consensus regarding a lower therapeutic threshold, this is not the case for the upper thresholds.


Our aim was to review available evidence related to upper thresholds.


We carried out an electronic search of different databases and a manual search of articles between 1960 and 2011, cross-referencing the following terms with clozapine—interactions, monitoring, pharmacokinetics, plasma levels, serum levels, and toxicity.


Sixty-nine articles met our search criteria and these could be divided into reviews (11), studies (24), and case reports (35). Study quality was evaluated, and none met criteria for a prospective, randomized controlled trial specifically addressing higher plasma levels, e.g., >500 ng/ml. Case reports emphasize in particular the impact of interactions, e.g., antidepressants and smoking. There is clear evidence indicating a dose-related increased risk of seizures, at least to 500–600 mg/day, but a lack of data to suggest such a relationship between plasma levels, dose, and side effects linked to safety, e.g., seizures, myocarditis, and agranulocytosis. The very limited evidence addressing an upper threshold related to clinical response suggests a “ceiling effect” in the range of 600–838 ng/ml.


It appears that the current safety-related threshold is not supported by evidence. There may be an upper threshold for clinical response, beyond which chance of response falls off, although further studies are warranted.


Clozapine levels Therapeutic threshold Safety-related threshold Toxicity Side effects Antipsychotics 


  1. American Psychiatric Association (2004) Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 161:1–56CrossRefGoogle Scholar
  2. Armstrong SC, Stephans JR (1997) Blood clozapine levels elevated by fluvoxamine: potential for side effects and lower clozapine dosage. J Clin Psychiatry 58:499PubMedCrossRefGoogle Scholar
  3. Bedry R, Deschamps L, Pehourcq F, Moore N, Pillet O, Favarel-Garrigues JC (1999) Non-fatal clozapine (LEPONEX) intoxication with toxicokinetic evaluation. Vet Hum Toxicol 41:20–22PubMedGoogle Scholar
  4. Bell R, McLaren A, Galanos J, Copolov D (1998) The clinical use of plasma clozapine levels. Aust N Z J Psychiatry 32:567–574PubMedCrossRefGoogle Scholar
  5. Bondolfi G, Dufour H, Patris M, May JP, Billeter U, Eap CB, Baumann P (1998) Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. Am J Psychiatry 155:499–504PubMedGoogle Scholar
  6. Brenner HD, Dencker SJ, Goldstein MJ, Hubbard JW, Keegan DL, Kruger G, Kulhanek F, Liberman RP, Malm U, Midha KK (1990) Defining treatment refractoriness in schizophrenia. Schizophr Bull 16:551–561PubMedCrossRefGoogle Scholar
  7. Broich K, Heinrich S, Marneros A (1998) Acute clozapine overdose: plasma concentration and outcome. Pharmacopsychiatry 31:149–151PubMedCrossRefGoogle Scholar
  8. Brouwers EE, Sohne M, Kuipers S, van Gorp EC, Schellens JH, Koks CH, Beijnen JH, Huitema AD (2009) Ciprofloxacin strongly inhibits clozapine metabolism: two case reports. Clin Drug Investig 29:59–63PubMedCrossRefGoogle Scholar
  9. Buckley PF, Friedman L, Krowinski AC, Eaton Y, Tronetti M, Miller DD (2001) Clinical and biochemical correlates of “high-dose” clozapine therapy for treatment-refractory schizophrenia. Schizophr Res 49:225–227PubMedCrossRefGoogle Scholar
  10. Buur-Rasmussen B, Brosen K (1999) Cytochrome P450 and therapeutic drug monitoring with respect to clozapine. Eur Neuropsychopharmacol 9:453–459PubMedCrossRefGoogle Scholar
  11. Canadian Psychiatric Association (2005) Clinical practice guidelines: treatment for schizophrenia. Can J Psychiatry 50:1S–56SGoogle Scholar
  12. Centorrino F, Baldessarini RJ, Flood JG, Kando JC, Frankenburg FR (1995) Relation of leukocyte counts during clozapine treatment to serum concentrations of clozapine and metabolites. Am J Psychiatry 152:610–612PubMedGoogle Scholar
  13. Centorrino F, Baldessarini RJ, Kando J, Frankenburg FR, Volpicelli SA, Puopolo PR, Flood JG (1994a) Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate. Am J Psychiatry 151:123–125PubMedGoogle Scholar
  14. Centorrino F, Baldessarini RJ, Kando JC, Frankenburg FR, Volpicelli SA, Flood JG (1994b) Clozapine and metabolites: concentrations in serum and clinical findings during treatment of chronically psychotic patients. J Clin Psychopharmacol 14:119–125PubMedCrossRefGoogle Scholar
  15. Chang WH, Augustin B, Lane HY, ZumBrunnen T, Liu HC, Kazmi Y, Jann MW (1999) In-vitro and in-vivo evaluation of the drug–drug interaction between fluvoxamine and clozapine. Psychopharmacology (Berl) 145:91–98CrossRefGoogle Scholar
  16. Chong SA, Remington GJ, Lee N, Mahendran R (2000) Contrasting clozapine prescribing patterns in the east and west? Ann Acad Med Singapore 29:75–78PubMedGoogle Scholar
  17. Chong SA, Tan CH, Lee HS (1997) Worsening of psychosis with clozapine and selective serotonin reuptake inhibitor combination: two case reports. J Clin Psychopharmacol 17:68–69PubMedCrossRefGoogle Scholar
  18. Cohen LG, Chesley S, Eugenio L, Flood JG, Fisch J, Goff DC (1996) Erythromycin-induced clozapine toxic reaction. Arch Intern Med 156:675–677PubMedCrossRefGoogle Scholar
  19. Combs MD, Perry PJ, Bever KA (1997) N-desmethylclozapine, an insensitive marker of clozapine-induced agranulocytosis and granulocytopenia. Pharmacotherapy 17:1300–1304PubMedGoogle Scholar
  20. Cooper TB (1996) Clozapine plasma level monitoring: current status. Psychiatr Q 67:297–311PubMedCrossRefGoogle Scholar
  21. Couchman L, Morgan PE, Spencer EP, Flanagan RJ (2010) Plasma clozapine, norclozapine, and the clozapine:norclozapine ratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1993–2007. Ther Drug Monit 32:438–447PubMedCrossRefGoogle Scholar
  22. Crilly J (2007) The history of clozapine and its emergence in the US market: a review and analysis. Hist Psychiatry 18:39–60PubMedCrossRefGoogle Scholar
  23. Darling P, Huthwaite MA (2011) Infection-associated clozapine toxicity. Clin Schizophr Relat Psychoses 5:159–160PubMedCrossRefGoogle Scholar
  24. De Berardis D, Serroni N, Campanella D, Olivieri L, Ferri F, Carano A, Cavuto M, Martinotti G, Cicconetti A, Piersanti M, Saverio Moschetta F, Di Giannantonio M (2012) Update on the adverse effects of clozapine: focus on myocarditis. Curr Drug Saf 7:55–62PubMedCrossRefGoogle Scholar
  25. de Leon J, Diaz FJ (2003) Serious respiratory infections can increase clozapine levels and contribute to side effects: a case report. Prog Neuropsychopharmacol Biol Psychiatry 27:1059–1063PubMedCrossRefGoogle Scholar
  26. de Leon J, Odom-White A, Josiassen RC, Diaz FJ, Cooper TB, Simpson GM (2003) Serum antimuscarinic activity during clozapine treatment. J Clin Psychopharmacol 23:336–341PubMedCrossRefGoogle Scholar
  27. Dequardo JR (2002) Modafinil-associated clozapine toxicity. Am J Psychiatry 159:1243–1244PubMedCrossRefGoogle Scholar
  28. Dequardo JR, Roberts M (1996) Elevated clozapine levels after fluvoxamine initiation. Am J Psychiatry 153:840–841PubMedGoogle Scholar
  29. Derenne JL, Baldessarini RJ (2005) Clozapine toxicity associated with smoking cessation: case report. Am J Ther 12:469–471PubMedCrossRefGoogle Scholar
  30. Devinsky O, Honigfeld G, Patin J (1991) Clozapine-related seizures. Neurology 41:369–371PubMedCrossRefGoogle Scholar
  31. DuMortier G, Lochu A, Colen de Melo P, Ghribi O, Roche-Rabreau D, DeGrassat K, Desce JM (1996) Elevated clozapine plasma concentrations after fluvoxamine initiation. Am J Psychiatry 153:738–739PubMedGoogle Scholar
  32. Fabrazzo M, La Pia S, Monteleone P, Mennella R, Esposito G, Pinto A, Maj M (2000) Fluvoxamine increases plasma and urinary levels of clozapine and its major metabolites in a time- and dose-dependent manner. J Clin Psychopharmacol 20:708–710PubMedCrossRefGoogle Scholar
  33. Farooq S, Nazar Z, Irfan M, Akhter J, Gul E, Irfan U, Naeem F (2011) Schizophrenia medication adherence in a resource-poor setting: randomised controlled trial of supervised treatment in out-patients for schizophrenia (STOPS). Br J Psychiatry 199:467–472PubMedCrossRefGoogle Scholar
  34. Farooq S, Taylor M (2011) Clozapine: dangerous orphan or neglected friend? Br J Psychiatry 198:247–249PubMedCrossRefGoogle Scholar
  35. Ferslew KE, Hagardorn AN, Harlan GC, McCormick WF (1998) A fatal drug interaction between clozapine and fluoxetine. J Forensic Sci 43:1082–1085PubMedGoogle Scholar
  36. Flanagan RJ, Spencer EP, Morgan PE, Barnes TR, Dunk L (2005) Suspected clozapine poisoning in the UK/Eire, 1992–2003. Forensic Sci Int 155:91–99PubMedCrossRefGoogle Scholar
  37. Freeman DJ, Oyewumi LK (1997) Will routine therapeutic drug monitoring have a place in clozapine therapy? Clin Pharmacokinet 32:93–100PubMedCrossRefGoogle Scholar
  38. Freudenreich O, Weiner RD, McEvoy JP (1997) Clozapine-induced electroencephalogram changes as a function of clozapine serum levels. Biol Psychiatry 42:132–137PubMedCrossRefGoogle Scholar
  39. Funderburg LG, Vertrees JE, True JE, Miller AL (1994) Seizure following addition of erythromycin to clozapine treatment. Am J Psychiatry 151:1840–1841PubMedGoogle Scholar
  40. Greenwood-Smith C, Lubman DI, Castle DJ (2003) Serum clozapine levels: a review of their clinical utility. J Psychopharmacol 17:234–238PubMedCrossRefGoogle Scholar
  41. Guitton C, Abbar M, Kinowski JM, Chabrand P, Bressolle F (1998) Multiple-dose pharmacokinetics of clozapine in patients with chronic schizophrenia. J Clin Psychopharmacol 18:470–476PubMedCrossRefGoogle Scholar
  42. Guitton C, Kinowski JM, Abbar M, Chabrand P, Bressolle F (1999) Clozapine and metabolite concentrations during treatment of patients with chronic schizophrenia. J Clin Pharmacol 39:721–728PubMedCrossRefGoogle Scholar
  43. Haack MJ, Bak ML, Beurskens R, Maes M, Stolk LM, Delespaul PA (2003) Toxic rise of clozapine plasma concentrations in relation to inflammation. Eur Neuropsychopharmacol 13:381–385PubMedCrossRefGoogle Scholar
  44. Haring C, Neudorfer C, Schwitzer J, Hummer M, Saria A, Hinterhuber H, Fleischhacker WW (1994) EEG alterations in patients treated with clozapine in relation to plasma levels. Psychopharmacology (Berl) 114:97–100CrossRefGoogle Scholar
  45. Harrison J, Janlov M, Wheeler AJ (2010) Patterns of clozapine prescribing in a mental health service in New Zealand. Pharm World Sci 32:503–511PubMedCrossRefGoogle Scholar
  46. Hasegawa M, Gutierrez-Esteinou R, Way L, Meltzer HY (1993) Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking. J Clin Psychopharmacol 13:383–390PubMedCrossRefGoogle Scholar
  47. Heeringa M, Beurskens R, Schouten W, Verduijn MM (1999) Elevated plasma levels of clozapine after concomitant use of fluvoxamine. Pharm World Sci 21:243–244PubMedCrossRefGoogle Scholar
  48. Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, Fric M, Gerlach M, Greiner C, Grunder G, Haen E, Havemann-Reinecke U, Jaquenoud Sirot E, Kirchherr H, Laux G, Lutz UC, Messer T, Muller MJ, Pfuhlmann B, Rambeck B, Riederer P, Schoppek B, Stingl J, Uhr M, Ulrich S, Waschgler R, Zernig G (2011) AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011. Pharmacopsychiatry 44:195–235CrossRefGoogle Scholar
  49. Hiemke C, Weigmann H, Hartter S, Dahmen N, Wetzel H, Muller H (1994) Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol 14:279–281PubMedCrossRefGoogle Scholar
  50. Hung GB, Cheung HK (2008) Predictors of high-dose antipsychotic prescription in psychiatric patients in Hong Kong. Hong Kong Med J 14:35–39PubMedGoogle Scholar
  51. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12PubMedCrossRefGoogle Scholar
  52. Jann MW, Grimsley SR, Gray EC, Chang WH (1993) Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinet 24:161–176PubMedCrossRefGoogle Scholar
  53. Jecel J, Michel TM, Gutknecht L, Schmidt D, Pfuhlmann B, Jabs BE (2005) Toxic clozapine serum levels during acute urinary tract infection: a case report. Eur J Clin Pharmacol 60:909–910PubMedCrossRefGoogle Scholar
  54. Jerling M, Lindstrom L, Bondesson U, Bertilsson L (1994) Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 16:368–374PubMedCrossRefGoogle Scholar
  55. Kane J, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789–796PubMedCrossRefGoogle Scholar
  56. Kane JM (1996) Treatment-resistant schizophrenic patients. J Clin Psychiatry 57(Suppl 9):35–40PubMedGoogle Scholar
  57. Kane JM, Leucht S, Carpenter D, Docherty JP (2003) The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry 64(12):5–19PubMedGoogle Scholar
  58. Keller S, Drexler H, Lichtenberg P (2009) Very high-dose clozapine and electroconvulsive therapy combination treatment in a patient with schizophrenia. J ECT 25:280–281PubMedCrossRefGoogle Scholar
  59. Khan AY, Preskorn SH (2005) Examining concentration-dependent toxicity of clozapine: role of therapeutic drug monitoring. J Psychiatr Pract 11:289–301PubMedCrossRefGoogle Scholar
  60. Koponen HJ, Leinonen E, Lepola U (1996) Fluvoxamine increases the clozapine serum levels significantly. Eur Neuropsychopharmacol 6:69–71PubMedCrossRefGoogle Scholar
  61. Kronig MH, Munne RA, Szymanski S, Safferman AZ, Pollack S, Cooper T, Kane JM, Lieberman JA (1995) Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. Am J Psychiatry 152:179–182PubMedGoogle Scholar
  62. Kuo FJ, Lane HY, Chang WH (1998) Extrapyramidal symptoms after addition of fluvoxamine to clozapine. J Clin Psychopharmacol 18:483–484PubMedCrossRefGoogle Scholar
  63. Lieberman JA, Safferman AZ, Pollack S, Szymanski S, Johns C, Howard A, Kronig M, Bookstein P, Kane JM (1994) Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 151:1744–1752PubMedGoogle Scholar
  64. Liu HC, Chang WH, Wei FC, Lin SK, Jann MW (1996) Monitoring of plasma clozapine levels and its metabolites in refractory schizophrenic patients. Ther Drug Monit 18:200–207PubMedCrossRefGoogle Scholar
  65. Maccall C, Billcliff N, Igbrude W, Natynczuk S, Spencer E, Flanagan R (2009) Clozapine: more than 900 mg/day may be needed. J Psychopharmacol 23:206–210PubMedCrossRefGoogle Scholar
  66. Mauri M, Volonteri LS, Fiorentini A, Invernizzi G, Nerini T, Baldi M, Bareggi SR (2004) Clinical outcome and plasma levels of clozapine and norclozapine in drug-resistant schizophrenic patients. Schizophr Res 66:197–198PubMedCrossRefGoogle Scholar
  67. Mauri MC, Rudelli R, Bravin S, Gianetti S, Giuliani E, Guerrini A, Orlandi R, Invernizzi G (1998) Clozapine metabolism rate as a possible index of drug-induced granulocytopenia. Psychopharmacology (Berl) 137:341–344CrossRefGoogle Scholar
  68. Mauri MC, Volonteri LS, Colasanti A, Fiorentini A, De Gaspari IF, Bareggi SR (2007) Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet 46:359–388PubMedCrossRefGoogle Scholar
  69. Mauri MC, Volonteri LS, Dell’Osso B, Regispani F, Papa P, Baldi M, Bareggi SR (2003) Predictors of clinical outcome in schizophrenic patients responding to clozapine. J Clin Psychopharmacol 23:660–664PubMedCrossRefGoogle Scholar
  70. Meeker JE, Herrmann PW, Som CW, Reynolds PC (1992) Clozapine tissue concentrations following an apparent suicidal overdose of Clozaril. J Anal Toxicol 16:54–56PubMedGoogle Scholar
  71. Meltzer HY, Bastani B, Kwon KY, Ramirez LF, Burnett S, Sharpe J (1989) A prospective study of clozapine in treatment-resistant schizophrenic patients. I. Preliminary report. Psychopharmacology (Berl) 99(Suppl):S68–S72CrossRefGoogle Scholar
  72. Miller DD (1991) Effect of phenytoin on plasma clozapine concentrations in two patients. J Clin Psychiatry 52:23–25PubMedGoogle Scholar
  73. Moore TA, Buchanan RW, Buckley PF, Chiles JA, Conley RR, Crismon ML, Essock SM, Finnerty M, Marder SR, Miller D, McEvoy JP, Robinson DG, Schooler NR, Shon SP, Stroup TS, Miller AL (2007) The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry 68:1751–1762PubMedCrossRefGoogle Scholar
  74. National Institute for Health and Clinical Experience (NICE) (2009) NICE clinical guideline 82—schizophrenia.Google Scholar
  75. Nielsen J, Damkier P, Lublin H, Taylor D (2011) Optimizing clozapine treatment. Acta Psychiatr Scand 123:411–422PubMedCrossRefGoogle Scholar
  76. Olesen OV (1998) Therapeutic drug monitoring of clozapine treatment. Therapeutic threshold value for serum clozapine concentrations. Clin Pharmacokinet 34:497–502PubMedCrossRefGoogle Scholar
  77. Olesen OV, Thomsen K, Jensen PN, Wulff CH, Rasmussen NA, Refshammer C, Sorensen J, Bysted M, Christensen J, Rosenberg R (1995) Clozapine serum levels and side effects during steady state treatment of schizophrenic patients: a cross-sectional study. Psychopharmacology (Berl) 117:371–378CrossRefGoogle Scholar
  78. Palmer BW, Loughran CI, Meeks TW (2010) Cognitive impairment among older patients with late-life schizophrenia or bipolar disorder. Continuum Lifelong Learning Neurol 16:135–152Google Scholar
  79. Paton C, Barnes TR, Cavanagh MR, Taylor D, Lelliott P (2008) High-dose and combination antipsychotic prescribing in acute adult wards in the UK: the challenges posed by p.r.n. prescribing. Br J Psychiatry 192:435–439PubMedCrossRefGoogle Scholar
  80. Paz E, Bouzas L, Hermida J, Brenlla J, Tutor JC (2008) Evaluation of three dosing models for the prediction of steady-state trough clozapine concentrations. Clin Biochem 41:603–606PubMedCrossRefGoogle Scholar
  81. Perry PJ, Miller DD, Arndt SV, Cadoret RJ (1991) Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 148:231–235PubMedGoogle Scholar
  82. Petersen L, Thorup A, Oqhlenschlaeger J, Christensen TO, Jeppesen P, Krarup G, Jorrgensen P, Mortensen EL, Nordentoft M (2008) Predictors of remission and recovery in a first-episode schizophrenia spectrum disorder sample: 2-year follow-up of the OPUS trial. Can J Psychiatry 53:660–670PubMedGoogle Scholar
  83. Pfuhlmann B, Hiemke C, Unterecker S, Burger R, Schmidtke A, Riederer P, Deckert J, Jabs B (2009) Toxic clozapine serum levels during inflammatory reactions. J Clin Psychopharmacol 29:392–394PubMedCrossRefGoogle Scholar
  84. Piscitelli SC, Frazier JA, McKenna K, Albus KE, Grothe DR, Gordon CT, Rapoport JL (1994) Plasma clozapine and haloperidol concentrations in adolescents with childhood-onset schizophrenia: association with response. J Clin Psychiatry 55(B):94–97PubMedGoogle Scholar
  85. Potkin SG, Bera R, Gulasekaram B, Costa J, Hayes S, Jin Y, Richmond G, Carreon D, Sitanggan K, Gerber B et al (1994) Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J Clin Psychiatry 55(B):133–136PubMedGoogle Scholar
  86. Raaska K, Raitasuo V, Arstila M, Neuvonen PJ (2002) Bacterial pneumonia can increase serum concentration of clozapine. Eur J Clin Pharmacol 58:321–322PubMedCrossRefGoogle Scholar
  87. Raja M (2011) Clozapine safety, 35 years later. Curr Drug Saf 6:164–184PubMedCrossRefGoogle Scholar
  88. Reith D, Monteleone JP, Whyte IM, Ebelling W, Holford NH, Carter GL (1998) Features and toxicokinetics of clozapine in overdose. Ther Drug Monit 20:92–97PubMedCrossRefGoogle Scholar
  89. Remington G (2010) Augmenting clozapine response in treatment-resistant schizophrenia. In: Meltzer HY, Elkis H (eds) Therapy-resistant schizophrenia. Karger, Basel, pp 129–151CrossRefGoogle Scholar
  90. Remington G, Saha A, Chong SA, Shammi C (2005) Augmentation strategies in clozapine-resistant schizophrenia. CNS Drugs 19:843–872PubMedCrossRefGoogle Scholar
  91. Sani G, Kotzalidis GD, Simonetti A, Solfanelli A, Mancinelli I, Calabro G, De Rossi P, De Luca O, Gentile G, Lionetto L, Manfredi G, Girardi N, Ambrosi E, Simmaco M, Tatarelli R (2010) Development of asymptomatic pancreatitis with paradoxically high serum clozapine levels in a patient with schizophrenia and the CYP1A2*1 F/1F genotype. J Clin Psychopharmacol 30:737–739PubMedCrossRefGoogle Scholar
  92. Sartorius A, Hewer W, Zink M, Henn FA (2002) High-dose clozapine intoxication. J Clin Psychopharmacol 22:91–92PubMedCrossRefGoogle Scholar
  93. Schulte P (2003) What is an adequate trial with clozapine?: therapeutic drug monitoring and time to response in treatment-refractory schizophrenia. Clin Pharmacokinet 42:607–618PubMedCrossRefGoogle Scholar
  94. Schwenger E, Dumontet J, Ensom MH (2011) Does olanzapine warrant clinical pharmacokinetic monitoring in schizophrenia? Clin Pharmacokinet 50:415–428PubMedCrossRefGoogle Scholar
  95. Seto K, Dumontet J, Ensom MH (2011) Risperidone in schizophrenia: is there a role for therapeutic drug monitoring? Ther Drug Monit 33:275–283PubMedCrossRefGoogle Scholar
  96. Simpson GM, Cooper TA (1978) Clozapine plasma levels and convulsions. Am J Psychiatry 135:99–100PubMedGoogle Scholar
  97. Sparshatt A, Taylor D, Patel MX, Kapur S (2010) A systematic review of aripiprazole-dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring. J Clin Psychiatry 71:1447–1456PubMedCrossRefGoogle Scholar
  98. Sparshatt A, Taylor D, Patel MX, Kapur S (2011) Relationship between daily dose, plasma concentrations, dopamine receptor occupancy, and clinical response to quetiapine: a review. J Clin Psychiatry 72:1108–1123PubMedCrossRefGoogle Scholar
  99. Sporn AL, Vermani A, Greenstein DK, Bobb AJ, Spencer EP, Clasen LS, Tossell JW, Stayer CC, Gochman PA, Lenane MC, Rapoport JL, Gogtay N (2007) Clozapine treatment of childhood-onset schizophrenia: evaluation of effectiveness, adverse effects, and long-term outcome. J Am Acad Child Adolesc Psychiatry 46:1349–1356PubMedCrossRefGoogle Scholar
  100. Stevens I, Gaertner HJ (1996) Plasma level measurement in a patient with clozapine intoxication. J Clin Psychopharmacol 16:86–87PubMedCrossRefGoogle Scholar
  101. Stroup TS, Lieberman JA, McEvoy JP, Davis SM, Swartz MS, Keefe RS, Miller AL, Rosenheck RA, Hsiao JK (2009) Results of phase 3 of the CATIE schizophrenia trial. Schizophr Res 107:1–12PubMedCrossRefGoogle Scholar
  102. Szegedi A, Anghelescu I, Wiesner J, Schlegel S, Weigmann H, Hartter S, Hiemke C, Wetzel H (1999) Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial. Pharmacopsychiatry 32:148–153PubMedCrossRefGoogle Scholar
  103. Takano A, Suhara T, Kusumi I, Takahashi Y, Asai Y, Yasuno F, Ichimiya T, Inoue M, Sudo Y, Koyama T (2006) Time course of dopamine D2 receptor occupancy by clozapine with medium and high plasma concentrations. Prog Neuropsychopharmacol Biol Psychiatry 30:75–81PubMedCrossRefGoogle Scholar
  104. Tandon R, Belmaker RH, Gattaz WF, Lopez-Ibor JJ Jr, Okasha A, Singh B, Stein DJ, Olie JP, Fleischhacker WW, Moeller HJ (2008) World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res 100:20–38PubMedCrossRefGoogle Scholar
  105. Taylor DM, Young C, Paton C (2003) Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. J Clin Psychiatry 64:30–34PubMedCrossRefGoogle Scholar
  106. Thorup M, Fog R (1977) Clozapine treatment of schizophrenic patients. Plasma concentration and coagulation factors. Acta Psychiatr Scand 55:123–126PubMedCrossRefGoogle Scholar
  107. Trappler B, Kwong V, Leeman CP (1996) Therapeutic effect of clozapine at an unusually high plasma level. Am J Psychiatry 153:133–134PubMedGoogle Scholar
  108. Uges DR, Boom K, Wientjes GD, Versteege J (2000) Therapeutic drug monitoring of clozapine: an unexpected outcome. Ther Drug Monit 22:323–324PubMedCrossRefGoogle Scholar
  109. Ulrich S, Wolf R, Staedt J (2003) Serum level of clozapine and relapse. Ther Drug Monit 25:252–255PubMedCrossRefGoogle Scholar
  110. van der Zwaag C, McGee M, McEvoy JP, Freudenreich O, Wilson WH, Cooper TB (1996) Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. Am J Psychiatry 153:1579–1584Google Scholar
  111. Wheeler AJ (2008) Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand. Ann Pharmacother 42:852–860PubMedCrossRefGoogle Scholar
  112. Wong J, Delva N (2007) Clozapine-induced seizures: recognition and treatment. Can J Psychiatry 52:457–463PubMedGoogle Scholar
  113. Wong JO, Leung SP, Mak T, Ng RM, Chan KT, Hon-Kee Cheung H, Choi WK, Lai J, Wai-Kiu Tsang A (2006) Plasma clozapine levels and clinical response in treatment-refractory Chinese schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 30:251–264PubMedCrossRefGoogle Scholar
  114. Yusufi B, Mukherjee S, Flanagan R, Paton C, Dunn G, Page E, Barnes TR (2007) Prevalence and nature of side effects during clozapine maintenance treatment and the relationship with clozapine dose and plasma concentration. Int Clin Psychopharmacol 22:238–243PubMedCrossRefGoogle Scholar
  115. Zhang WV, D’Esposito F, Edwards RJ, Ramzan I, Murray M (2008) Interindividual variation in relative CYP1A2/3A4 phenotype influences susceptibility of clozapine oxidation to cytochrome P450-specific inhibition in human hepatic microsomes. Drug Metab Dispos 36:2547–2555PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Gary Remington
    • 1
    • 2
    • 3
  • Ofer Agid
    • 1
    • 2
  • George Foussias
    • 1
    • 2
    • 3
  • Larissa Ferguson
    • 1
  • Krysta McDonald
    • 1
  • Valerie Powell
    • 1
  1. 1.Schizophrenia Program, Centre for Addiction and Mental Health (CAMH)TorontoCanada
  2. 2.Department of Psychiatry, Faculty of MedicineUniversity of TorontoTorontoCanada
  3. 3.Institute of Medical Science, School of Graduate StudiesUniversity of TorontoTorontoCanada

Personalised recommendations